申请人:Rigel Pharmaceuticals, Inc.
公开号:US08299087B2
公开(公告)日:2012-10-30
The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.
本发明涵盖具有I式的化合物以及使用这些化合物治疗调节JAK通路或抑制JAK激酶,特别是JAK3,在治疗中具有治疗用途的组合物和方法。